These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25155604)

  • 1. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
    Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
    Ford SL; Chen YC; Lou Y; Borland J; Min SS; Yuen GJ; Shelton MJ
    Antimicrob Agents Chemother; 2008 Feb; 52(2):534-8. PubMed ID: 18056271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
    Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC
    Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.
    Song IH; Borland J; Chen S; Savina P; Peppercorn AF; Piscitelli S
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4394-7. PubMed ID: 23817375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
    Cotton M; Cassim H; Pavía-Ruz N; Garges HP; Perger T; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Sievers J; Cheng K
    Pediatr Infect Dis J; 2014 Jan; 33(1):57-62. PubMed ID: 23811743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
    Corbett AH; Patterson KB; Tien HC; Kalvass LA; Eron JJ; Ngo LT; Lim ML; Kashuba AD
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2756-61. PubMed ID: 16870769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
    Shelton MJ; Ford SL; Borland J; Lou Y; Wire MB; Min SS; Xue ZG; Yuen G
    J Acquir Immune Defic Syndr; 2006 May; 42(1):61-7. PubMed ID: 16639341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
    Barbour AM; Gibiansky L; Wire MB
    J Clin Pharmacol; 2014 Feb; 54(2):206-14. PubMed ID: 25272370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.
    Song I; Borland J; Min S; Lou Y; Chen S; Patel P; Wajima T; Piscitelli SC
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3517-21. PubMed ID: 21555764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
    Shelton MJ; Wire MB; Lou Y; Adamkiewicz B; Min SS
    Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
    Ross LL; Song IH; Arya N; Choukour M; Zong J; Huang SP; Eley T; Wynne B; Buchanan AM
    BMC Infect Dis; 2016 Jul; 16():347. PubMed ID: 27450277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
    Pérez-Elías MJ; Morellon ML; Ortega E; Hernández-Quero J; Rodríguez-Torres M; Clotet B; Felizarta F; Gutiérrez F; Pineda JA; Nichols G; Lou Y; Wire MB
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5185-96. PubMed ID: 19667283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
    Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
    AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
    Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
    Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.